Do analysts recommend ASMB or CPIX?

Assembly Biosciences presently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Assembly Biosciences (ASMB) Competitors

$24.44 +0.29 (+1.20%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$23.65 -0.79 (-3.23%)

As of 06/18/2026 06:49 PM Eastern

Compare

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

Should you buy Assembly Biosciences stock or one of its competitors? MarketBeat compares Assembly Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assembly Biosciences include Pacira BioSciences (PCRX), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Pacira BioSciences had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Pacira BioSciences and 1 mentions for Assembly Biosciences. Pacira BioSciences' average media sentiment score of 0.97 beat Assembly Biosciences' score of -1.00 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pacira BioSciences	Positive
Assembly Biosciences	Negative

Pacira BioSciences has a net margin of 0.70% compared to Assembly Biosciences' net margin of -8.98%. Pacira BioSciences' return on equity of 10.24% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Pacira BioSciences has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Pacira BioSciences currently has a consensus target price of $29.40, suggesting a potential upside of 31.66%. Assembly Biosciences has a consensus target price of $44.00, suggesting a potential upside of 80.03%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 5.3% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacira BioSciences has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.21	$7.03M	$0.12	186.08
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A

Summary

Pacira BioSciences beats Assembly Biosciences on 11 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Omeros?

Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Assembly Biosciences presently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Omeros has a consensus price target of $40.33, suggesting a potential upside of 292.35%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Omeros had 3 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.16 beat Assembly Biosciences' score of -1.00 indicating that Omeros is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Omeros	Neutral

Assembly Biosciences has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Omeros	N/A	-102.16%	64.87%

Omeros has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	14.69

Summary

Omeros beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Assembly Biosciences has a net margin of -8.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Assembly Biosciences' return on equity of -4.21% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Assembly Biosciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

In the previous week, Assembly Biosciences and Assembly Biosciences both had 1 articles in the media. Cumberland Pharmaceuticals' average media sentiment score of 0.37 beat Assembly Biosciences' score of -1.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Cumberland Pharmaceuticals	Neutral

Cumberland Pharmaceuticals has lower revenue, but higher earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Cumberland Pharmaceuticals	$44.52M	1.92	-$2.84M	-$0.49	N/A

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Assembly Biosciences presently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Assembly Biosciences beats Cumberland Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Assembly Biosciences compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Eli Lilly and Company has a net margin of 34.98% compared to Assembly Biosciences' net margin of -8.98%. Eli Lilly and Company's return on equity of 105.77% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Eli Lilly and Company has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	15.88	$20.64B	$28.15	39.03
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Eli Lilly and Company had 169 more articles in the media than Assembly Biosciences. MarketBeat recorded 170 mentions for Eli Lilly and Company and 1 mentions for Assembly Biosciences. Eli Lilly and Company's average media sentiment score of 1.00 beat Assembly Biosciences' score of -1.00 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Overall Sentiment
Eli Lilly and Company	Positive
Assembly Biosciences	Negative

Eli Lilly and Company currently has a consensus target price of $1,227.74, indicating a potential upside of 11.74%. Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 80.03%. Given Assembly Biosciences' higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Eli Lilly and Company has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Summary

Eli Lilly and Company beats Assembly Biosciences on 14 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Johnson & Johnson?

Assembly Biosciences (NASDAQ:ASMB) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Johnson & Johnson has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	5.37	-$6.12M	-$0.11	N/A
Johnson & Johnson	$94.19B	5.84	$26.80B	$8.65	26.40

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 80.03%. Johnson & Johnson has a consensus price target of $253.04, suggesting a potential upside of 10.81%. Given Assembly Biosciences' higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

In the previous week, Johnson & Johnson had 120 more articles in the media than Assembly Biosciences. MarketBeat recorded 121 mentions for Johnson & Johnson and 1 mentions for Assembly Biosciences. Johnson & Johnson's average media sentiment score of 1.33 beat Assembly Biosciences' score of -1.00 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Negative
Johnson & Johnson	Positive

Assembly Biosciences has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Johnson & Johnson has a net margin of 21.83% compared to Assembly Biosciences' net margin of -8.98%. Johnson & Johnson's return on equity of 32.60% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Johnson & Johnson	21.83%	32.60%	13.29%

Summary

Johnson & Johnson beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$383.81M	$5.70B	$6.66B	$12.38B
Dividend Yield	N/A	0.69%	2.68%	5.68%
P/E Ratio	-222.16	7.25	24.49	24.42
Price / Sales	5.37	23.49	574.28	128.85
Price / Cash	N/A	8.19	44.20	55.24
Price / Book	1.87	4.13	10.71	6.58
Net Income	-$6.12M	$99.67M	$3.57B	$337.29M
7 Day Performance	6.45%	0.75%	0.73%	0.60%
1 Month Performance	-7.84%	5.65%	3.97%	5.00%
1 Year Performance	42.59%	122.03%	28.54%	31.05%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	2.0261 of 5 stars	$24.44 +1.2%	$44.00 +80.0%	+42.6%	$383.81M	$72.30M	N/A	100	Negative News
PCRX Pacira BioSciences	4.2089 of 5 stars	$23.36 -0.2%	$29.40 +25.8%	-7.5%	$918.78M	$734.86M	194.60	720
OMER Omeros	3.432 of 5 stars	$10.41 +2.1%	$40.33 +287.4%	+219.3%	$754.87M	$9.89M	14.90	210	Gap Up
CPIX Cumberland Pharmaceuticals	0.7249 of 5 stars	$5.68 +3.6%	N/A	+6.7%	$85.09M	$44.52M	N/A	80
LLY Eli Lilly and Company	4.6038 of 5 stars	$1,167.65 +2.8%	$1,227.74 +5.1%	+40.1%	$1.10T	$65.18B	41.55	50,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

How does Assembly Biosciences compare to Pacira BioSciences?

Summary

How does Assembly Biosciences compare to Omeros?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Summary

How does Assembly Biosciences compare to Johnson & Johnson?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. PCRX, OMER, CPIX, LLY, and JNJ

How does Assembly Biosciences compare to Pacira BioSciences?

Does the media prefer PCRX or ASMB?

Is PCRX or ASMB more profitable?

Which has more risk & volatility, PCRX or ASMB?

Do analysts recommend PCRX or ASMB?

Do insiders & institutionals have more ownership in PCRX or ASMB?

Which has stronger valuation & earnings, PCRX or ASMB?

Summary

How does Assembly Biosciences compare to Omeros?

Do institutionals and insiders hold more shares of ASMB or OMER?

Do analysts rate ASMB or OMER?

Does the media favor ASMB or OMER?

Which has more risk and volatility, ASMB or OMER?

Is ASMB or OMER more profitable?

Which has stronger earnings and valuation, ASMB or OMER?

Summary

How does Assembly Biosciences compare to Cumberland Pharmaceuticals?

Is ASMB or CPIX more profitable?

Which has more risk & volatility, ASMB or CPIX?

Does the media favor ASMB or CPIX?

Which has preferable earnings and valuation, ASMB or CPIX?

Do institutionals & insiders have more ownership in ASMB or CPIX?

Do analysts recommend ASMB or CPIX?

Summary

How does Assembly Biosciences compare to Eli Lilly and Company?

Is LLY or ASMB more profitable?

Which has higher valuation & earnings, LLY or ASMB?

Do insiders and institutionals believe in LLY or ASMB?

Does the media refer more to LLY or ASMB?

Do analysts rate LLY or ASMB?

Which has more volatility and risk, LLY or ASMB?

Summary

How does Assembly Biosciences compare to Johnson & Johnson?

Which has stronger valuation and earnings, ASMB or JNJ?

Do analysts rate ASMB or JNJ?

Does the media favor ASMB or JNJ?

Which has more risk and volatility, ASMB or JNJ?

Do insiders & institutionals believe in ASMB or JNJ?

Is ASMB or JNJ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools